Cargando…

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease

OBJECTIVE: Cognitive decline occurs in multiple neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD). Shared underlying mechanisms may exist and manifest as shared biomarker signatures. Previously, we nominated plasma epidermal growth factor (EGF) as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Nicholas S., Swanson, Christine R., Cherng, Hua‐Ren, Unger, Travis L., Xie, Sharon X., Weintraub, Daniel, Marek, Ken, Stern, Matthew B., Siderowf, Andrew, Trojanowski, John Q., Chen‐Plotkin, Alice S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863747/ https://www.ncbi.nlm.nih.gov/pubmed/27231704 http://dx.doi.org/10.1002/acn3.299

Ejemplares similares

Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson’s Disease
por: Gallagher, Julia, et al.
Publicado: (2021)

An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia
por: Berlyand, Yosef, et al.
Publicado: (2016)

Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia
por: Akhtar, Rizwan S., et al.
Publicado: (2017)

Characterization of Parkinson’s disease using blood-based biomarkers: A multicohort proteomic analysis
por: Posavi, Marijan, et al.
Publicado: (2019)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Genetic prediction of impulse control disorders in Parkinson's disease
por: Weintraub, Daniel, et al.
Publicado: (2022)

Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
por: Henderson, Michael X., et al.
Publicado: (2019)

Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?
por: Tropea, Thomas F., et al.
Publicado: (2021)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Plasma phosphorylated tau181 predicts cognitive and functional decline
por: Tropea, Thomas F., et al.
Publicado: (2022)

Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype
por: Cooper, Christine A., et al.
Publicado: (2016)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
por: Bartl, Michael, et al.
Publicado: (2021)

Cognitive Declines Precede and Predict Functional Declines in Aging and Alzheimer’s Disease
por: Zahodne, Laura B., et al.
Publicado: (2013)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Predictive value of abbreviated olfactory tests in prodromal Parkinson disease
por: Vaswani, Pavan A., et al.
Publicado: (2023)

Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer’s Disease
por: Gottesman, Reena T., et al.
Publicado: (2019)

Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
por: Mizutani, Yasuaki, et al.
Publicado: (2023)

Proposal for a Biologic Staging System of Parkinson’s Disease
por: Chahine, Lana M., et al.
Publicado: (2023)

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated
por: Robinson, John L, et al.
Publicado: (2023)

Capturing Subjective Mild Cognitive Decline in Parkinson’s Disease
por: Rosenblum, Sara, et al.
Publicado: (2022)

Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
por: Trojanowski, John Q
Publicado: (2013)

Updating Our Definitions of Parkinson’s Disease for a Molecular Age
por: Chen-Plotkin, Alice S., et al.
Publicado: (2018)

Treatment Strategies and Quality-of-Care Indicators for Patients With Parkinson's Disease
por: Chen, Jack J., et al.
Publicado: (2009)

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease
por: Cousins, Katheryn A. Q., et al.
Publicado: (2023)

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
por: Caspell-Garcia, Chelsea, et al.
Publicado: (2017)

Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
por: Sandelius, Åsa, et al.
Publicado: (2018)

Progression of Cognitive Decline in Parkinson’s Disease
por: Roheger, Mandy, et al.
Publicado: (2018)

Sarcosine May Induce EGF Production or Inhibit the Decline in EGF Concentrations in Patients with Chronic Schizophrenia (Results of the PULSAR Study)
por: Pawlak, Agnieszka, et al.
Publicado: (2023)

Validating virtual administration of neuropsychological testing in Parkinson disease: a pilot study
por: Gallagher, Julia, et al.
Publicado: (2023)

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
por: Brumm, Michael C., et al.
Publicado: (2023)

The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease
por: Stutzbach, Lauren D, et al.
Publicado: (2013)

Periodontitis and Cognitive Decline in Alzheimer’s Disease
por: Ide, Mark, et al.
Publicado: (2016)

Is the risk of Alzheimer’s disease and dementia declining?
por: Langa, Kenneth M
Publicado: (2015)

Reversal of cognitive decline in Alzheimer's disease
por: Bredesen, Dale E., et al.
Publicado: (2016)

Cognitive Decline: Not Always Alzheimer’s Disease
por: Villalba, Noel Lorenzo, et al.
Publicado: (2018)

Baseline concentration of misfolded α‐synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson's disease
por: Ning, H., et al.
Publicado: (2018)

Correlation between serum IGF-1 and EGF levels and neuropsychiatric and cognitive in Parkinson’s disease patients
por: Shi, Xiaoxue, et al.
Publicado: (2022)

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013)

Progressive decline of glucocerebrosidase in aging and Parkinson's disease
por: Rocha, Emily M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hr957gskclsdi2s8upvf3d3a8u